Madrigal Pays $50M to License Pfizer’s Phase 2 DGAT-2 Inhibitor Ervogastat for MASH
Madrigal Pharmaceuticals secured an exclusive global license for Pfizer’s PF-06865571 (ervogastat), a Phase 2 oral DGAT-2 inhibitor for MASH, paying $50 million upfront plus potential milestone and royalty payments. Madrigal plans drug‐drug interaction studies and FDA consultation on a 2026 Phase 2 combination trial with Rezdiffra.
Related News
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
CNS
Cohen & Steers Partners with J.P. Morgan on Short-Duration Hybrid Credit Fund Expansion
CNS•
SHEL
Shell ex-dividend cuts FTSE 100 by 6.84 points
SHEL•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
Sources
FGB